Robust Engraftment With Mgta-456, a CD34+ Expanded Cell Therapy Product in Patients With Inherited Metabolic Disorders (IMD): Preliminary Phase 2 Trial Results

Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2018.12.171
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Perioperative Immunomodulation With Interleukin-2 in Patients With Renal Cell Carcinoma: Results of a Controlled Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
2006English

Inherited Metabolic Disorders

British Medical Bulletin
Medicine
1983English

Respiratory Manifestations in Patients With Inherited Metabolic Diseases

European Respiratory Review
PulmonaryRespiratory Medicine
2013English

Outcome of Patients With Inherited Neurotransmitter Disorders

Canadian Journal of Neurological Sciences
MedicineNeurology
2018English

A Phase 2 Trial of Sunitinib in Patients With Advanced Non–clear Cell Renal Cell Carcinoma

European Urology
Urology
2012English

Outcomes After Second or Greater Hematopoietic Stem Cell Transplantation in Children With Inherited Metabolic Disorders

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Abstract LB-A10: Preliminary Results From a Phase 2 Proof of Concept Trial of Tipifarnib in Tumors With HRAS Mutations

2018English

Improving Bone Health in Men With Prostate Cancer Receiving Androgen Deprivation Therapy: Results of a Randomized Phase 2 Trial

Cancer
Cancer ResearchOncology
2017English

A Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy